Richter Lifts Guidance as CNS, Biotech and a GLP-1 Strategy Converge
Gedeon Richter upgrades 2026 Pharma Clean EBIT to double-digit constant-currency growth, powered by Vraylar royalties and biosimilar momentum, while FX and Eastern Europe remain the drags.
GEDSF · Earnings Call · 2026-08-06
Guidance Upgrade Underneath FX Noise
Gedeon Richter's Q2 2026 report was framed by a "significant foreign exchange headwind," but management was quick to pivot to what matters: "constant currency Clean EBIT is up by 21% in the first half" and, more boldly, "we are upgrading 2026 Pharma Clean EBIT and now expect double-digit growth on a constant currency basis, so somewhere in the teens." That is a genuine step-change from the earlier plan, and the confidence comes from across the business. The company also delivered record free cash flow, a sign that operational discipline is finally paying off.The ex-CNS margin is the key metric that management has been telegraphing for years, and the improvement is now tangible. The guidance upgrade is partly Vraylar, partly biotech, and partly a broader cost transformation that is showing up in COGS, SG&A, and R&D.some of this is driven by outstanding growth in CNS, but you will remember that our main KPI is the ex-CNS margin, and our Q2 numbers should give us reassurance that we are taking a meaningful step this year to close the gap between where we are and where we want to be
The Engines: CNS and Biotech
CNS remains the star. Vraylar, sold via AbbVie, is still growing 19% year-on-year and is "close to $2 billion" per AbbVie's disclosure, while Richter's own Reagila grew 25% as it took over more territories. The Vraylar royalty stream is a reliable cash engine, and the company is now pushing hard on a pipeline of CNS compounds, including RGH-202 moving into Phase II. Biotech has also exceeded expectations. “Biotech exceeded expectations on the back of successful launches and strong partner sales.” — Gabor Orban, Chief Executive Officer · 2026-08-06 Revenue grew 30% on a constant-currency basis, driven by teriparatide and recent biosimilar launches. The company is confident it can break even at the latest next year, a major milestone given the heavy investment of the past few years. The business units are finally showing the operating leverage that the multiyear efficiency programs were designed to create.GenMed and Eastern Europe: The Persistent Laggards
Not everything is firing. General Medicines remains the only business unit that is below plan. “General Medicines remain the only business unit that was below our original plans.” — Gabor Orban, Chief Executive Officer · 2026-08-06 The weakness is concentrated in Eastern Europe, where the company is dealing with legacy portfolio erosion, distributor inventory rationalization, and the tail of a weak flu season. CEO Gabor Orban was candid: “Eastern Europe. The extent to which it's a consequence of those efficiency programs, not. There is a very minor contribution from portfolio pruning to Eastern European and Central Asian revenues.” — Gabor Orban, Chief Executive Officer · 2026-08-06 He attributes the slowdown to three factors: the ongoing erosion of older products, the rationalization of wholesaler inventories, and the temporary impact of last year's distribution shocks. Management expects a return to mid-single-digit growth by 2027, but the recovery is clearly a process, not an event. The API restructuring is tied to these efficiency efforts. The company has been consolidating its API manufacturing, shrinking the Budapest site dramatically. As the CEO explained, “we decided in 2022 to create a fit-for-purpose infrastructure and fit-for-purpose organization, which in plain English means the rightsizing, shrinking of the infrastructure for API.” — Gabor Orban, Chief Executive Officer · 2026-08-06 This has cut energy use by 54% and headcount, and it is contributing to the margin improvement. The Budapest site will go from four plants to effectively half a plant, with most production moved to Dorog.A New Front: GLP-1 and Women's Health
The most strategically interesting development is Richter's move into GLP-1s, which it frames as a natural extension of its women's health franchise. The company has been building a portfolio through partnerships, including with Adalvo. The logic is spelled out by the CEO:This is a company-specific bet that ties into the broader global theme of GLP 1 in pharma, but it is far from a me-too move. Richter is positioning itself to benefit from the gender skew of GLP-1 usage — women are the majority of patients, and gynecologists are often the prescribers. The company also gets pre-LOE license fees and milestones through its out-licensing model, which means cash flows can start before patent expiry. That is a smart way to de-risk what is otherwise a 2030s opportunity. The company is also expanding its women's health portfolio with Fylrevy, a new product launched in three markets, and has a growing pipeline in menopause (Lenzetto). The combination of GLP-1 and women's health is a differentiated strategy among European pharma companies, and it sets up Richter to be a leader in the “longevity” space. All in all, this is a company that is managing the FX storm well, upgrading guidance, and quietly building a compelling future. The market has not been rewarded with price appreciation (the stock is flat-ish, per the tape), but the fundamental story is strengthening. If the GenMed recovery materializes and biotech breaks even, Richter could be a much more profitable company in 2027 than it is today.GLP-1s are a focus area for the GenMed business unit... And when they go off patent in the 2030s, GLP-1s will be one of the – if not the most important quality of life and longevity products.